Normal view MARC view ISBD view

Vinblastine improves outcoe in children with anaplastic large cell lymphoma(ALCL) treated with a uniform short duration intensive protocol

In Pediatric Blood and Cancer
Contributor(s): Parikh PM | Kurkure PA | Magrath I | Adde M | Kolhatkar B | Pai SK | Bansal S | Vora T | Hingmire S | Arora B | Tata memorial hospital, Pediatric Oncology, Mumbai, India | Banavali SD.
Material type: materialTypeLabelArticleSeries: Vol 49 Issues 4.Publisher: 2007Description: 532.Subject(s): Anaplastic large cell lymphoma | Vinblastine | MCP 842 Protocol | DDC classification: In: Pediatric Blood and CancerSummary: Objective. MCP 842 Protocol, a short duration intensive chemotherapy protocol was initiated at our centre 1 n 1987. Vinblastine was substituted for Vincristine in our protocol for these patients with ALCL from 2004 onwards. We present the survival benefit of Vinblastine in this protocol. Methods. A total of 27 previously untreated patients of anaplastic large cell lymphoma (ALCL) were enrolled on MCP-842 protocol between 1987 and 2006. Treatment consisted of eight alternating cycles of two regimens, A (Cyclophosphamide, Adriamycin, Vincristine and Cytosine-arabinoside) and B (Etoposide, Vincristine, Methotrexate, and Ifosfamide). Intrathecal methotrexate and cytosine arabinoside were administered in the first 4 cycles. No radiotherapy was given. Of these, 8 patients(post 2004) received Vinblastine in place of vincristine (the rest of the protocol remained unchanged) Results. The median age was 14 years (range 2.620 years). The male to female ratio was 4.5:1. Common disease sites included: Abdomen-33%; p
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR7469

Objective. MCP 842 Protocol, a short duration intensive chemotherapy protocol was initiated at our centre 1 n 1987. Vinblastine was substituted for Vincristine in our protocol for these patients with ALCL from 2004 onwards. We present the survival benefit of Vinblastine in this protocol.
Methods. A total of 27 previously untreated patients of anaplastic large cell lymphoma (ALCL) were enrolled on MCP-842 protocol between 1987 and 2006.
Treatment consisted of eight alternating cycles of two regimens, A (Cyclophosphamide, Adriamycin, Vincristine and Cytosine-arabinoside) and B (Etoposide, Vincristine, Methotrexate, and Ifosfamide). Intrathecal methotrexate and cytosine arabinoside were administered in the first 4 cycles. No radiotherapy was given. Of these, 8 patients(post 2004) received Vinblastine in place of vincristine (the rest of the protocol remained unchanged)
Results. The median age was 14 years (range 2.620 years). The male to female ratio was 4.5:1. Common disease sites included: Abdomen-33%; p

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha